 In December 2019, Kodiak Sciences Inc NASDAQ: KOD entered into a funding agreement with Baker Bros Advisors LP, wherein Baker Bros agreed to fund up to 225 million in exchange for the right to 4.5 royalties on Kodiaks potential future net sales of KSI-301 and certain other products. The royalty was capped at 4.5 times the total amount funded under the Funding Agreement. 